Neoastilbin

CAS No. 54081-47-9

Neoastilbin ( —— )

Catalog No. M24527 CAS No. 54081-47-9

Neoastilbin may have antioxidant and anti-inflammatory activities, it shows potent inhibition of lens aldose reductase.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 426 In Stock
10MG 611 In Stock
25MG 888 In Stock
50MG 1242 In Stock
100MG 1701 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Neoastilbin
  • Note
    Research use only, not for human use.
  • Brief Description
    Neoastilbin may have antioxidant and anti-inflammatory activities, it shows potent inhibition of lens aldose reductase.
  • Description
    Neoastilbin may have antioxidant and anti-inflammatory activities, it shows potent inhibition of lens aldose reductase.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    54081-47-9
  • Formula Weight
    450.4
  • Molecular Formula
    C21H22O11
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C[C@@H]([C@@H]([C@H]([C@H]1O)O)O)O[C@H]1O[C@@H]([C@H](c(cc1)cc(O)c1O)Oc1c2c(O)cc(O)c1)C2=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Antioxidant and Anti-Inflammatory Activities of Phenolic-Enriched Extracts of Smilax glabra.Evid Based Complement Alternat Med. 2014;2014:910438.
molnova catalog
related products
  • Ganoderic acid F

    Ganoderic acid F inhibits the proliferation of HeLa human cervical carcinoma cells with IC(50) values of 19.5+/-0.6 microM.

  • N20C hydrochloride

    NMDA receptor antagonist.

  • TMN355

    TMN355 is a potent chemical inhibitor of cyclophilin A and reduces foam cell formation and cytokine secretion,and is used for atherosclerosis. Silencing cyclophilin A in THP-1 cells and human monocytes using siRNA or chemical inhibitor, TMN355 resulted in decrease in lipid uptake by 65-75% even after exposure to oxidized LDL.